Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.

A new pill designed to help with weight loss and blood sugar ... to produce in large amounts. Lilly's injectable GLP-1 drug ...

Shares of Eli Lilly soared Thursday morning after the ... as significant weight loss, with participants on the highest dosage losing 16 pounds on average during just the 40-week trial–similar ...

Lilly said weight loss ... doses. After 40 weeks of treatment in the multi-dose trial, Lilly said once-daily orforglipron showed body weight reductions of 4.7% at 3 mg, 6.1% with 12 mg, and ...

(Bloomberg) -- Eli Lilly & Co. shares surged after its experimental pill helped ... or 7.9% of their body weight, over a 40-week period. That was more than similar patients shed in earlier studies ...

(Bloomberg) -- Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well ... or 7.9% of their body weight, over a 40-week period. That compares favorably ...

STOCKS VOLATILE AFTER POWELL'S TARIFF WARNING, TRUMP FIRES BACK: LIVE UPDATES Shares of Eli Lilly jumped 16% on the news. Eli Lilly released new data around a daily weight-loss pill, showing it ...

Orforglibron, a pill form of GLP-1 weight loss injections ... Lilly’s clinical trial included 559 people with Type 2 diabetes. People who took orforglibron for 40 weeks saw their blood sugars ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...